BioForm Medical to Announce Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008, and Host Confe
January 16 2008 - 6:30AM
PR Newswire (US)
SAN MATEO, Calif., Jan. 16 /PRNewswire-FirstCall/ -- BioForm
Medical, Inc. (NASDAQ:BFRM) announced that on Thursday, January 31,
2008, it will report it financial results for the quarter ended
December 31, 2007, which is its second quarter fiscal year 2008.
The Company will issue the earnings press release after the NASDAQ
Global Market closes and will hold a conference call with investors
at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). BioForm Medical
Chief Executive Officer Steve Basta and Chief Financial Officer
Derek Bertocci will discuss the Company's results for the quarter
ended December 31, 2007. The conference call will be webcast live
on the Investor Relations section of BioForm Medical's website at
http://www.bioform.com/. The online archive of the broadcast will
be available approximately 90 minutes after the live call and will
continue to be available for four weeks. The conference call may be
accessed by dialing 888-670-2248 for callers in the U.S. and
913-905-3226 for international callers. Please notify the operator
that you would like to join "BioForm Medical's Second Quarter
Earnings Call" and provide the participant code "7132314", if
prompted. About BioForm Medical, Inc.: BioForm Medical, Inc. is a
medical aesthetics company headquartered in San Mateo, California.
BioForm is dedicated to bringing doctors and their patients safe
and effective products for use in the dermatology, plastic surgery
and ENT markets. BioForm's products include Radiesse(R), a
long-lasting filler for use in facial aesthetics and vocal fold
insufficiency, and Coaptite(R) for treating female stress urinary
incontinence which is marketed through a partnership with Boston
Scientific Corporation. BioForm has licensed U.S. marketing rights
to Aethoxysklerol(R), the worldwide leading sclerotherapy agent,
which is currently being evaluated in a Phase III clinical trial.
BioForm has also licensed BioGlue, a new surgical adhesive product
for plastic surgery applications, which is being developed in a
partnership with CryoLife, Inc. Contact: Adam Gridley 650.286.4025
Vice President, Corporate Development BioForm Medical, Inc.
DATASOURCE: BioForm Medical, Inc. CONTACT: Adam Gridley, Vice
President, Corporate Development of BioForm Medical, Inc.,
+1-650-286-4025 Web site: http://www.bioformmedical.com/
Copyright
Bioform Medical (MM) (NASDAQ:BFRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioform Medical (MM) (NASDAQ:BFRM)
Historical Stock Chart
From Jul 2023 to Jul 2024